
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is a leading medical device company with a diverse product portfolio and a global presence. Their focus on less invasive medical devices gives them a competitive edge in the market, and their recent M&A activity shows potential for future growth. However, there are risks such as stiffer macroeconomic headwinds and potential challenges with their WATCHMAN product line. Despite these risks, Boston Scientific's current valuation appears accommodating, making it an attractive investment opportunity with potential for upside in the future.
Bears say
Boston Scientific is a company that specializes in manufacturing and marketing medical devices for various procedures, including coronary IVL, interventional oncology, and neuromodulation. The company has a global reach and has been facing challenges in its WATCHMAN sales. The company's risks include competition, market share loss, and potential regulatory delays. Despite these challenges, Boston Scientific's diverse product portfolio and cost reduction efficiencies should lead to double-digit earnings growth. However, the potential for slower electrophysiology and WATCHMAN sales could be a risk to the company's growth targets. As a result, the company's forecasted earnings for 2027 have been adjusted and we have lowered our price target to $57 from $77.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares